Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome

American Journal of Gastroenterology

Volumn 103, Issue 10, 2008, Pages 2562-2569

  Drossman, Douglas A ^a   Danilewitz, Mervyn ^b   Næsdal, Jørgen ^c   Hwang, Clara ^b   Adler, John ^c   Silberg, Debra G ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 7371; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; ROBALZOTAN; SERTRALINE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; AGITATION; ANGER; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; BURNING SENSATION; CLINICAL TRIAL; CONFUSION; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPERSONALIZATION; DEPRESSION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSKINESIA; DYSPHORIA; FEAR; FEMALE; FORMICATION; HEADACHE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABLE COLON; LETHARGY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MOOD DISORDER; MULTICENTER STUDY; NERVOUSNESS; NIGHTMARE; PARANOIA; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSORY DYSFUNCTION; SIDE EFFECT; SINUSITIS; SOMNOLENCE; TREMOR; VISUAL HALLUCINATION;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BENZOPYRANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTOR, SEROTONIN, 5-HT1A; TREATMENT OUTCOME;

EID: 53149147052     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.02115.x     Document Type: Article

References (33)

1. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006 130 : 1480 91.
2. Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: A systematic review. Am J Gastroenterol 2002 97 : 1910 5.
3. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005 11 (1 Suppl S17 26.
4. Drossman D, Morris CB, Hu Y, et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007 102 : 1442 53.
5. Cain KC, Headstrom P, Jarrett ME, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol 2006 101 : 124 32.
6. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 31.
7. Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 2006 130 : 1447 58.
8. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005 39 (5 Suppl S184 93.
9. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol 2004 141 : 1285 93.
10. Moses PL, Coates MD, Mahoney CR, et al. Key elements of serotonin signaling are altered in IBD and IBS: Support for a molecular basis of the irritable bowel syndrome. Am J Gastroenterol 2003 98 (Suppl S262 3.
11. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005 3 : 349 57.
12. 3 receptor antagonist. Aliment Pharmacol Ther 1999 13 : 1149 59.
13. Tack J, Muller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005 54 : 1707 13.
14. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial. Lancet 2000 355 : 1035 40.
15. Heading R, Bardhan K, Hollerbach S, et al. Systematic review: The safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther 2006 24 : 207 36.
16. 1A receptor antagonist, NAD-299. J Pharmacol Exp Ther 1997 283 : 216 25.
17. Drossman DA. Brain imaging and its implications for studying centrally targeted treatments in irritable bowel syndrome: A primer for gastroenterologists. Gut 2005 54 : 569 73.
18. Wiklund IK, Fullerton S, Hawkey CJ, et al. An irritable bowel syndrome-specific symptom questionnaire: Development and validation. Scand J Gastroenterol 2003 38 : 947 54.
19. Labus JS, Bolus R, Chang L, et al. The Visceral Sensitivity Index: Development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther 2004 20 : 89 97.
20. Gordon S, Ameen V, Bagby B, et al. Validation of irritable bowel syndrome Global Improvement Scale: An integrated symptom end point for assessing treatment efficacy. Dig Dis Sci 2003 48 : 1317 23.
21. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994 47 : 81 7.
22. Longstreth GF, Bolus R, Naliboff B, et al. Impact of irritable bowel syndrome on patients' lives: Development and psychometric documentation of a disease-specific measure for use in clinical trials. Eur J Gastroenterol Hepatol 2005 17 : 411 20.
23. Lanfumey L, Hamon M. 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 2004 3 : 1 10.
24. Bueno L, Fioramonti J. Visceral perception: Inflammatory and non-inflammatory mediators. Gut 2002 51 (Suppl 1 I19 23.
25. Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003 27 : 1159 72.
26. 1A receptor and the stimulus effects of LSD in the rat. Psychopharmacology (Berl) 2005 182 : 197 204.
27. 3 receptors in the rat spinal cord dorsal horn. Neuroscience 2005 135 : 1255 68.
28. Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets 2006 7 : 139 47.
29. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: Reports from a spontaneous reporting system. Drug Saf 1999 20 : 277 87.
30. AHFS_Drugs_Information. Bethesda, MD : American Society of Health-System Pharmacists, 2007.
31. Cancelli I, Marcon G, Balestrieri M. Factors associated with complex visual hallucinations during antidepressant treatment. Hum Psychopharmacol 2004 19 : 577 84.
32. 1A receptor antagonist NAD-299. Results from an 8-week placebo and paroxetine-controlled study. Eur Neuropsychopharmacol 2003 13 (Suppl 4 S189.
33. Mayer EA, Bradesi S, Chang L, et al. Functional GI disorders: From animal models to drug development. Gut 2008 57 : 384 404.